Global Diabetes Pen Market, By Product Type (Insulin Pens, Insulin Pen Needle), Usage (Reusable Pens, Disposable Pens), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics) - Industry Trends and Forecast to 2031.
Diabetes Pen Market Analysis and Size
The rise in the population of diabetes patients across the globe is among the important factors expected to intensify the growth and demand of the diabetes pen market. In addition, the high demand for human insulin analog and the rise in the incidence of needle stick injury are also expected to contribute to the growth in the market. Also, the reimbursement for diabetes management and rapid technological advancement in the production of diabetes pens are also likely to enhance the growth of the market. Furthermore, the rise in the particular treatments for cancer along with easy access to a large proportion of medicines are also among the significant factors expected to fuel the growth of the diabetes pen market.
Data Bridge Market Research analyzes that the global diabetes pen market, which was USD 10.13 billion in 2023, is likely to reach USD 22.99 billion by 2031 and is expected to undergo a CAGR of 8.9% during the forecast period. “Retail Pharmacy" dominates the distribution channel segment of the market. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Insulin Pens, Insulin Pen Needle), Usage (Reusable Pens, Disposable Pens), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa
|
|
Market Players Covered
|
AstraZeneca (U.K.), BD (U.S.), Eli Lilly and Company (U.S.), Biocon (India), Sanofi (France), Jiangsu Delfu Medical Device Co., Ltd. (China), Owen Mumford (U.K.), Wockhardt Limited (India) (India), Smiths Group plc (U.K.), Nipro Europe Group Companies (Netherlands), Novo Nordisk India Pvt Ltd. (India), InjexUK (U.K.), MannKind Corporation (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Copernicus (Poland), Ypsomed AG (Switzerland), HTL-STREFA S.A. (Poland), Merck & Co., Inc. (U.S.), Bayer AG (Germany)
|
|
Market Opportunities
|
|
Market Definition
The diabetes pens are largely used to inject insulin for the treatment of diabetes. It is basically composed of an insulin cartridge, which is incorporated or bought separately, and a dial to quantify the dose, and is also used with disposable pen needles to deliver the dose.
Global Diabetes Pen Market Dynamics
Drivers
- Growing Prevalence of Diabetes
The increasing global incidence of diabetes is a major driver for the diabetes pen market. As more individuals are diagnosed with diabetes, the demand for convenient and effective insulin delivery devices like diabetes pens is on the rise.
- Advancements in Diagnostic Technologies
Ongoing advancements in diabetes pen technologies, such as the development of smart insulin pens and connected devices, are enhancing user experience and adherence to insulin therapy. These innovations contribute to market growth.
- Patient Preference for Non-invasive Delivery
Patients often prefer non-invasive and user-friendly insulin delivery options. Diabetes pens offer a less invasive alternative to traditional insulin syringes, driving their adoption among patients.
Opportunities
- Increasing Awareness and Education
Opportunities lie in increasing awareness about the benefits of diabetes pens and providing education to healthcare professionals and patients. This can enhance acceptance and adoption.
- Focus on Emerging Markets
There is significant growth potential in emerging markets where diabetes prevalence is rising. Manufacturers can explore opportunities in these regions by offering cost-effective and user-friendly diabetes pen solutions.
Restraints
- High Cost of Smart Insulin Pens
While smart insulin pens offer advanced features such as dose tracking and connectivity, they can be expensive. The high cost of these devices can limit their adoption, particularly in regions with budget constraints.
- Limited Adoption in Developing Regions
Access to advanced healthcare technologies, including diabetes pens, may be limited in developing regions due to economic constraints and inadequate healthcare infrastructure.
Global Diabetes Pen Market Scope
The diabetes pen market is segmented on the basis of product type, usage, application and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Product type
- Insulin Pens
- Insulin Pen Needle.
Usage
- Reusable Pens
- Disposable Pens
Application
- Type 1 Diabetes
- Type 2 Diabetes
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Sales
- Diabetes Clinics.
Diabetes Pen Market Regional Analysis/Insights
The diabetes pen market is analyzed and market size insights and trends are provided by country, product type, usage, application and distribution channel as referenced above.
The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East & Africa.
North America is expected to dominate the market due to the rise in the diabetic population and better awareness and reimbursement policy for diabetes management.
Asia-Pacific is expected to show the fastest growth due to surging government initiatives to spread awareness and increase the geriatric population in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The diabetes pen market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for diabetes pen market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on diabetes pen market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Diabetes Pen Market Share Analysis
The diabetes pen market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetes pen market.
Some of the major players operating in the diabetes pen market are:
- AstraZeneca (U.K.)
- BD (U.S.)
- Eli Lilly and Company (U.S.)
- Biocon (India)
- Sanofi (France)
- Jiangsu Delfu Medical Device Co., Ltd. (China)
- Owen Mumford (U.K.)
- Wockhardt Limited (India) (India)
- Smiths Group plc (U.K.)
- Nipro Europe Group Companies (Netherlands)
- Novo Nordisk India Pvt Ltd. (India)
- InjexUK (U.K.)
- MannKind Corporation (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Copernicus (Poland)
- Ypsomed AG (Switzerland)
- HTL-STREFA S.A. (Poland)
- Merck & Co., Inc. (U.S.)
- Bayer AG (Germany)
SKU-